Although a limited number of such public neoantigens have been validated as immunogenic, the evidence discussed in this review strongly supports the hypothesis that these neoantigens are actionable and targetable with TCR T cell–based therapies or, as recently described, with bispecific antibodies that contain two binding domains, one derived from a TCR-mimic antibody highly specific for a distinct peptide/MHC complex that can target the tumor, and a second for CD3 that can capture and activate proximal T cells (Douglass et al. 2021, Hsiue et al. 2021). The gene discussed is HLA-C; the disease is neoplasm.